Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American ...
December 09 2019 - 4:05PM
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced a presentation
highlighting preclinical data on its novel NMDA receptor modulator,
NYX-783. The data exhibit robust effects of NYX-783 on conditioned
fear in PTSD models and on alcohol consumption in a stress-induced
alcohol seeking model. The studies were conducted in collaboration
with the Medical University of South Carolina and Northwestern
University. The presentation is taking place today, December 9,
2019, at the Annual Meeting of the American College of
Neuropsychopharmacology in Orlando, Florida.
“We continue to observe preclinical effects of NYX-783 that
strongly support its ongoing clinical development as a treatment
for PTSD,” said Norbert Riedel, Ph.D., president and chief
executive officer of Aptinyx. “In addition to bolstering our
understanding of the positive effects of NYX-783 on learning and
memory processes, these data highlight its potential utility in
treating a common comorbidity of PTSD—alcohol use disorder. As we
seek to understand the full therapeutic potential of NYX-783, it is
very encouraging to see these data demonstrating its activity
across multiple facets of such a complex condition.”
“The data observed with Aptinyx’s NYX-783 in this model are very
intriguing,” said Justin T. Gass, Ph.D., assistant professor of
neuroscience at the Medical University of South Carolina. “The
novel mechanism of NYX-783 appears to have differentiated effects
on learning and memory processes and significantly reduced
stress-induced alcohol-seeking behavior in rats. Importantly,
NYX-783 also significantly reduced relapse-like behavior in this
model. Together, these data are supportive of further evaluation of
NYX-783 and its potential utility in substance abuse conditions
such as alcohol use disorder.”
Presentation Details:
Presentation Title: The Novel
N-methyl-D-aspartate Receptor Modulator NYX-783 Exhibits
Therapeutic Effects in Rodent Models Useful for the Study of
Post-Traumatic Stress Disorder and Comorbid Alcohol Use
DisorderPoster Number: 247Presenter:
M. Scott Bowers, Ph.D., Aptinyx Inc. Poster
Presentation: Monday, December 9,
5:30 p.m. – 7:30 p.m. ET
About NYX-783 NYX-783 is a novel, oral NMDA
receptor modulator currently in Phase 2 development for the
treatment of post-traumatic stress disorder (PTSD). In preclinical
studies of NYX-783, particularly strong results were observed in
psychiatric models, models of fear extinction, and models of
substance abuse. In a Phase 1 clinical study of NYX-783, ample
central nervous system exposure was observed and the product
candidate demonstrated a favorable safety and tolerability profile,
with no serious adverse effects, across a wide dose range. The
U.S. Food and Drug Administration has granted Fast Track
designation to the development of NYX-783 for the treatment of
PTSD.
About AptinyxAptinyx Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development, and commercialization of proprietary synthetic small
molecules for the treatment of brain and nervous system
disorders. Aptinyx has a platform for discovery of novel
compounds that work through a unique mechanism to modulate—rather
than block or over-activate—NMDA receptors and enhance synaptic
plasticity, the foundation of neural cell communication. The
company has three product candidates in clinical development in
central nervous system indications, including chronic pain,
post-traumatic stress disorder, and cognitive impairment associated
with Parkinson’s disease. Aptinyx is also advancing
additional compounds from its proprietary discovery platform, which
continues to generate a rich and diverse pipeline of small-molecule
NMDA receptor modulators with the potential to treat an array of
neurologic disorders. For more information,
visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, therapeutic effects of the company’s product
candidates, expectations regarding the design, implementation,
timing, and success of its current and planned clinical trials,
expectations regarding its preclinical development activities, and
expectations regarding its uses and sufficiency of capital. Risks
that contribute to the uncertain nature of the forward-looking
statements include: the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy;
regulatory developments in the United States and foreign countries;
as well as those risks and uncertainties set forth in the company’s
most recent annual report on Form 10-K and in its other filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Aptinyx
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Investor Contacts:Nick SmithAptinyx
Inc.ir@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024